Articles by James Calloway
uniQure Shares Soar on FDA Leadership Shift Amid Gene Therapy Dispute
uniQure shares jumped 34% in premarket trading following news that FDA biologics chief Vinay Prasad will depart in April. The move comes amid a regulatory standoff over the company's Huntington's disease gene therapy.
3D Systems Tops Q4 Forecasts, but Bleak Q1 Outlook Raises Doubts
3D Systems reported Q4 revenue of $106.3M, exceeding its forecast, though full-year sales fell 12%. The company anticipates a revenue decline and continued losses for the current quarter.
Palantir Faces Pentagon AI Ban Fallout as Defense Tech Reliance Questioned
Palantir Technologies confronts new risks as the U.S. Pentagon designates AI supplier Anthropic a supply-chain threat, raising concerns over its defense software dependencies. Broader market jitters add to the pressure.
Broadcom's AI Surge Faces Market Test After Strong Outlook
Broadcom's AI revenue jumped 106% to $8.4 billion last quarter, with a new $10.7 billion target set for the current period. The chipmaker's stock will be tested as investors digest its aggressive growth forecast amid broader market declines.
Mesoblast Surges on Ryoncil Sales, Sets $120M Revenue Target
Mesoblast Limited's stock climbed 3% in early U.S. trading following strong first-half results fueled by its newly launched cell therapy Ryoncil. The company has established a fiscal 2026 revenue target of $110-120 million for the product.
Sea Stock Retreats as Shopee's Slower Growth Outlook Raises Spending Concerns
Sea Ltd's stock gave back some of its prior-day gains after the company projected slower gross merchandise volume growth for its Shopee unit in 2026 alongside a significant quarterly cost increase, prompting investor reassessment of its spending plans.
Okta's Q4 Results Top Estimates, Yet Growth Outlook Hits Post-IPO Low
Okta reported Q4 revenue of $761 million, up 11%, and adjusted EPS of $0.90, both exceeding expectations. However, the company forecast just 9% revenue growth for the current quarter, its slowest since going public.
Rentokil Posts Higher Profit, Boosts Termite Provision as Chair Plans Exit
Rentokil Initial announced a 4% increase in adjusted pretax profit for 2025, driven by improved North American performance. The company also significantly raised its provision for termite damage claims and revealed its chairman will step down.
Tango Therapeutics Soars on Erasca Partnership and Q4 Update
Tango Therapeutics shares jumped 36% following news of a strategic partnership with Erasca to develop vopimetostat for pancreatic and lung cancers, alongside its fourth-quarter financial update.
Kenvue Grants Executive Stock Awards Amid $40B Kimberly-Clark Acquisition Wait
Kenvue has issued new restricted stock unit awards to top executives, including North America head Carlos De Jesus and General Counsel Matthew Orlando, while awaiting regulatory approval for its $40 billion acquisition by Kimberly-Clark.